vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and SOUNDHOUND AI, INC. (SOUN). Click either name above to swap in a different company.

SOUNDHOUND AI, INC. is the larger business by last-quarter revenue ($55.1M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). SOUNDHOUND AI, INC. runs the higher net margin — 72.8% vs -3.7%, a 76.4% gap on every dollar of revenue. On growth, SOUNDHOUND AI, INC. posted the faster year-over-year revenue change (59.4% vs 33.4%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-22.3M). Over the past eight quarters, SOUNDHOUND AI, INC.'s revenue compounded faster (117.9% CAGR vs 17.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

SoundHound AI, Inc. is an American music and speech recognition company based in Santa Clara, California. It was originally founded as Melodis in 2005 before rebranding to SoundHound Inc. in 2010, and SoundHound AI in 2022.

GYRE vs SOUN — Head-to-Head

Bigger by revenue
SOUN
SOUN
1.5× larger
SOUN
$55.1M
$37.2M
GYRE
Growing faster (revenue YoY)
SOUN
SOUN
+25.9% gap
SOUN
59.4%
33.4%
GYRE
Higher net margin
SOUN
SOUN
76.4% more per $
SOUN
72.8%
-3.7%
GYRE
More free cash flow
GYRE
GYRE
$16.5M more FCF
GYRE
$-5.8M
$-22.3M
SOUN
Faster 2-yr revenue CAGR
SOUN
SOUN
Annualised
SOUN
117.9%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
SOUN
SOUN
Revenue
$37.2M
$55.1M
Net Profit
$-1.4M
$40.1M
Gross Margin
95.3%
47.9%
Operating Margin
0.3%
77.3%
Net Margin
-3.7%
72.8%
Revenue YoY
33.4%
59.4%
Net Profit YoY
-340.1%
115.5%
EPS (diluted)
$-0.01
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
SOUN
SOUN
Q4 25
$37.2M
$55.1M
Q3 25
$30.6M
$42.0M
Q2 25
$26.8M
$42.7M
Q1 25
$22.1M
$29.1M
Q4 24
$27.9M
$34.5M
Q3 24
$25.5M
$25.1M
Q2 24
$25.2M
$13.5M
Q1 24
$27.2M
$11.6M
Net Profit
GYRE
GYRE
SOUN
SOUN
Q4 25
$-1.4M
$40.1M
Q3 25
$5.9M
$-109.3M
Q2 25
$1.6M
$-74.7M
Q1 25
$3.7M
$129.9M
Q4 24
$569.0K
$-258.6M
Q3 24
$2.9M
$-21.8M
Q2 24
$4.5M
$-37.3M
Q1 24
$9.9M
$-33.0M
Gross Margin
GYRE
GYRE
SOUN
SOUN
Q4 25
95.3%
47.9%
Q3 25
94.7%
42.6%
Q2 25
95.7%
39.0%
Q1 25
95.9%
36.5%
Q4 24
95.8%
39.9%
Q3 24
96.2%
48.6%
Q2 24
96.9%
63.0%
Q1 24
96.4%
59.7%
Operating Margin
GYRE
GYRE
SOUN
SOUN
Q4 25
0.3%
77.3%
Q3 25
22.7%
-275.6%
Q2 25
8.1%
-182.9%
Q1 25
10.3%
Q4 24
2.4%
-744.2%
Q3 24
16.6%
-134.6%
Q2 24
12.7%
-163.3%
Q1 24
29.7%
-246.1%
Net Margin
GYRE
GYRE
SOUN
SOUN
Q4 25
-3.7%
72.8%
Q3 25
19.4%
-259.9%
Q2 25
5.9%
-175.1%
Q1 25
16.9%
446.1%
Q4 24
2.0%
-748.6%
Q3 24
11.2%
-86.7%
Q2 24
18.0%
-277.2%
Q1 24
36.6%
-284.7%
EPS (diluted)
GYRE
GYRE
SOUN
SOUN
Q4 25
$-0.01
$-0.13
Q3 25
$0.03
$-0.27
Q2 25
$0.00
$-0.19
Q1 25
$0.00
$0.31
Q4 24
$0.00
$-0.75
Q3 24
$0.01
$-0.06
Q2 24
$0.01
$-0.11
Q1 24
$0.03
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
SOUN
SOUN
Cash + ST InvestmentsLiquidity on hand
$52.4M
$248.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$463.8M
Total Assets
$166.1M
$688.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
SOUN
SOUN
Q4 25
$52.4M
$248.5M
Q3 25
$60.0M
$268.9M
Q2 25
$54.4M
$230.3M
Q1 25
$29.9M
$245.8M
Q4 24
$26.7M
$198.2M
Q3 24
$25.1M
$135.6M
Q2 24
$25.1M
$200.2M
Q1 24
$37.4M
$211.7M
Total Debt
GYRE
GYRE
SOUN
SOUN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
$85.5M
Stockholders' Equity
GYRE
GYRE
SOUN
SOUN
Q4 25
$106.0M
$463.8M
Q3 25
$101.9M
$399.2M
Q2 25
$92.0M
$359.8M
Q1 25
$68.1M
$397.0M
Q4 24
$63.3M
$182.7M
Q3 24
$63.2M
$296.0M
Q2 24
$60.4M
$223.9M
Q1 24
$56.6M
$155.5M
Total Assets
GYRE
GYRE
SOUN
SOUN
Q4 25
$166.1M
$688.2M
Q3 25
$159.4M
$702.2M
Q2 25
$152.6M
$579.5M
Q1 25
$129.8M
$587.5M
Q4 24
$125.4M
$554.0M
Q3 24
$125.2M
$499.7M
Q2 24
$120.9M
$266.7M
Q1 24
$122.0M
$287.4M
Debt / Equity
GYRE
GYRE
SOUN
SOUN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
SOUN
SOUN
Operating Cash FlowLast quarter
$-5.6M
$-21.9M
Free Cash FlowOCF − Capex
$-5.8M
$-22.3M
FCF MarginFCF / Revenue
-15.5%
-40.4%
Capex IntensityCapex / Revenue
0.4%
0.7%
Cash ConversionOCF / Net Profit
-0.55×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$-99.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
SOUN
SOUN
Q4 25
$-5.6M
$-21.9M
Q3 25
$4.7M
$-32.7M
Q2 25
$2.1M
$-24.5M
Q1 25
$-129.0K
$-19.2M
Q4 24
$-2.8M
$-33.1M
Q3 24
$1.7M
$-35.3M
Q2 24
$-5.5M
$-18.5M
Q1 24
$2.9M
$-21.9M
Free Cash Flow
GYRE
GYRE
SOUN
SOUN
Q4 25
$-5.8M
$-22.3M
Q3 25
$4.0M
$-32.8M
Q2 25
$1.8M
$-24.7M
Q1 25
$-251.0K
$-19.3M
Q4 24
$-2.8M
$-33.2M
Q3 24
$1.0M
$-35.5M
Q2 24
$-6.9M
$-18.7M
Q1 24
$2.7M
$-22.0M
FCF Margin
GYRE
GYRE
SOUN
SOUN
Q4 25
-15.5%
-40.4%
Q3 25
13.1%
-78.1%
Q2 25
6.8%
-57.8%
Q1 25
-1.1%
-66.4%
Q4 24
-10.1%
-96.1%
Q3 24
4.1%
-141.6%
Q2 24
-27.5%
-139.1%
Q1 24
9.8%
-190.2%
Capex Intensity
GYRE
GYRE
SOUN
SOUN
Q4 25
0.4%
0.7%
Q3 25
2.2%
0.4%
Q2 25
1.0%
0.4%
Q1 25
0.6%
0.6%
Q4 24
0.2%
0.2%
Q3 24
2.7%
0.9%
Q2 24
5.8%
1.8%
Q1 24
0.9%
0.9%
Cash Conversion
GYRE
GYRE
SOUN
SOUN
Q4 25
-0.55×
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
-0.15×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

SOUN
SOUN

Hosted Services$37.7M68%
Licensing$12.6M23%
Professional Service$4.6M8%

Related Comparisons